-
Posted by
Two Blokes Apr 28 -
Filed in
Stock
-
1 view
German healthcare and materials group Merck KGaA said on Monday it struck a deal to acquire U.S. biotech firm SpringWorks Therapeutics for an equity value of $3.9 billion to boost its cancer drug business.
